Keyphrases
Granulocyte Colony-stimulating Factor (G-CSF)
100%
Case-cohort Study
100%
COVID-19
100%
Lenzilumab
100%
Severe Coronavirus Disease 2019
100%
Clinical Outcomes
16%
Inflammatory Markers
16%
Untreated Patients
16%
Disease Severity
8%
Risk Factors
8%
Hospitalized Patients
8%
Patient Matched
8%
Randomized Placebo-controlled Trial
8%
High Risk
8%
Adverse Events
8%
Patient Characteristics
8%
Interleukin-6
8%
Poor Outcome
8%
Clinical Endpoints
8%
Acute Respiratory Distress Syndrome
8%
C-reactive Protein
8%
Severe Pneumonia
8%
Myeloid Cells
8%
Oxygen Saturation
8%
Investigational New Drug Application
8%
Oxygenation
8%
Hospital Discharge
8%
Clinical Improvement
8%
Inspired Oxygen
8%
Treatment-related Adverse Events
8%
Absolute Lymphocyte Count
8%
In-hospital Death
8%
Cytokine Analysis
8%
Laboratory Outcomes
8%
Markers of Disease Severity
8%
Time to Clinical Improvement
8%
Medicine and Dentistry
Cohort Analysis
100%
COVID-19
100%
Neutralization
100%
Granulocyte Macrophage Colony Stimulating Factor
100%
Lenzilumab
100%
Disease Severity
16%
Adverse Event
16%
Placebo
8%
Cytokine
8%
Interleukin 6
8%
Acute Respiratory Distress Syndrome
8%
C Reactive Protein
8%
Myeloid Cell
8%
Oxygen Saturation
8%
Controlled Clinical Trial
8%
Patient Characteristics
8%
Clinical Endpoint
8%
Fraction of Inspired Oxygen
8%
Lymphocyte
8%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Granulocyte Macrophage Colony Stimulating Factor
100%
Lenzilumab
100%
Coronavirinae
100%
Diseases
100%
Adverse Event
16%
Disease Severity
16%
Placebo
8%
Cytokine
8%
Interleukin 6
8%
Adult Respiratory Distress Syndrome
8%
C Reactive Protein
8%
Controlled Clinical Trial
8%